

## Section 3 Alternative Scenario Analyses

### Supplementary Material 22 Scenario analyses

	Costs	QALYs	ICER		Costs	QALYs	ICER
<b>Lifetime costs</b>				<b>EQ-5D-5L preference values – life-time horizon</b>			
Control	£48,295.50	17.79359		Control	£642.06	17.82590	
SWAL only	£48,361.39	17.80341	£6,706	SWAL only	£691.19	17.83591	£4,908
SWAL plus desk	£48,444.07	17.80778	£18,956	SWAL plus desk	£747.60	17.84282	£8,164
<b>Linear efficacy decay*</b>				<b>EQ-5D-5L preference values - within-trial time horizon</b>			
Control	£642.06	17.79359		Control	£642.06	0.87474	
SWAL only	£691.19	17.80737	£3,565	SWAL only	£691.19	0.87896	£11,644
SWAL plus desk	£747.60	17.81472	£7,674	SWAL plus desk	£747.60	0.87703	Dominated
<b>70% efficacy decay (per annum)</b>				<b>No differential within-trial cost or QALYs estimates</b>			
Control	£642.06	17.79359		Control	£587.42	17.79532	
SWAL only	£691.19	17.80171	£6,046	SWAL only	£668.01	17.80111	£13,914
SWAL plus desk	£747.60	17.80298	£44,597	SWAL plus desk	£815.40	17.80913	£18,382
<b>60% efficacy decay (per annum)</b>				<b>1.5% discount rate</b>			
Control	£642.06	17.79359		Control	£646.26	24.20423	
SWAL only	£691.19	17.80254	£5,487	SWAL only	£692.71	24.21901	£3,143
SWAL plus desk	£747.60	17.80492	£23,683	SWAL plus desk	£748.50	24.22765	£6,455
<b>40% efficacy decay (per annum)</b>				<b>30 years-old</b>			
Control	£642.06	17.79359		Control	£744.01	21.18629	
SWAL only	£691.19	17.80520	£4,231	SWAL only	£783.76	21.19302	£5,903.00
SWAL plus desk	£747.60	17.81197	£8,330	SWAL plus desk	£826.24	21.19101	Dominated
<b>30% efficacy decay (per annum)</b>				<b>40 years-old</b>			
Control	£642.06	17.79359		Control	£667.96	18.87570	
SWAL only	£691.19	17.80781	£3,455	SWAL only	£716.39	18.88404	£5,805
SWAL plus desk	£747.60	17.81906	£5,016	SWAL plus desk	£770.86	18.88595	£28,602
<b>20% efficacy decay (per annum)</b>				<b>50 years-old</b>			

Control	£642.06	17.79359		Control	£603.97	16.03678	
SWAL only	£691.19	17.81400	£2,407	SWAL only	£655.99	16.05092	£3,680
SWAL plus desk	£747.60	17.83461	£2,737	SWAL plus desk	£718.06	16.05774	£9,099
<b>10% efficacy decay (per annum)</b>				<b>60 years-old</b>			
Control	£642.06	17.79359		Control	£550.85	12.72221	
SWAL only	£691.19	17.83321	Ext dominated	SWAL only	£602.53	12.74258	£2,537
SWAL plus desk	£747.60	17.88543	£1,080	SWAL plus desk	£671.68	12.76031	£3,899
<b>0% efficacy decay (per annum)</b>				<b>70 years-old</b>			
Control	£642.06	17.79359		Control	£504.50	9.05734	
SWAL only	£691.19	17.99396	Ext dominated	SWAL only	£560.21	9.08821	£1,805
SWAL plus desk	£747.60	18.26384	£209	SWAL plus desk	£635.86	9.12269	£2,194
<b>Patterson et al (2018) estimates</b>				<b>Male</b>			
Control	£642.06	17.79359		Control	£478.49	17.30132	
SWAL only	£691.19	17.79834	£10,342	SWAL only	£534.78	17.31386	£4,488
SWAL plus desk	£747.60	17.79494	Dominated	SWAL plus desk	£613.77	17.32035	£12,186
<b>Multi-level modelling</b>				<b>Female</b>			
Control	£655.92	17.79448		Control	£726.83	17.99817	
SWAL only	£733.89	17.80323	£8,909	SWAL only	£765.16	18.00801	£3,892
SWAL plus desk	£803.55	17.80739	£16,763	SWAL plus desk	£810.88	18.01039	£19,280
<b>Multi-level modelling within-trial time horizon</b>							
Control	£655.92	0.84332					
SWAL only	£733.89	0.84628	£26,345				
SWAL plus desk	£803.55	0.84159	Dominated				

\*(5-year effect - 20% decay per annum)